http://www.usamci.com text only  

University of South Alabama

Page Content   Main Links

Contact Us   Links   Map & Driving Directions   Home   USA College of Medicine   USA Home
Eddie Reed, M.D.

Clinical Director and Point Clear Charities Chair,
Abraham Mitchell Distinguished Investigator,
and Professor of Oncologic Sciences

Office:
USA Mitchell Cancer Institute
1660 Springhill Avenue
Mobile, AL. 36604
(251) 445-9863
eddiereed@usouthal.edu

Research Interests:
-DNA damage and repair, as it relates to the clinical use of anticancer agents and to human carcinogens. Particular emphasis is given to the identification and manipulation of factors that modulate DNA damage levels and DNA repair efficiency.
-The treatment of gynecologic and genitourinary malignancies.
-New agent development.
-The science of health care disparity.
-The clinical, molecular, and public health aspects of cancer prevention.

Honors and Academic Achievements:
-2011                Top Doctors, U S News & World Report listing
-2010 – 2014  Member, External Advisory Board, NIMHD, NIH, Bethesda, MD
-2008 – 2011  Member, National Board of Advisors, AACR, Philadelphia, PA
-2005 – 2008  Member, Institute of Medicine National Cancer Policy Forum
-2005 – 2008  Member, C-Change, Washington, D.C.

Education:
-Fellowship, Medical Oncology, NCI, Bethesda, Maryland, 1985
-Internship and Residency, Stanford University, Palo Alto, California, 1981
-M.D., Yale University, New Haven, Connecticut, 1979
-B.S., Philander Smith College, Little Rock, Arkansas, 1975

Professional Appointments:
-1985 – 1987 Special Assistant for Preclinical Science, Office of the Director (B. A. Chabner, Dir) Division of Cancer Treatment, NCI, Bethesda, Maryland
-1987 – 2001 Senior Staff, USPHS (tenured scientist 1991-2001); Division of Clinical Sciences, NCI (Medicine Branch and Clinical Pharmacology Branch)
-1993 – 1996 Chief, Clinical Pharmacology Branch, Division of Clinical Sciences (DCS), NCI
-1993 – 2001 Chief, Ovarian Cancer and Metastatic Prostate Cancer Clinic, DCS, NCI
-2001 – 2005 Director, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, W V
-2005 – 2008 Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
-2008 –present Professor, Oncologic Sciences; and, Abraham Mitchell Distinguished Investigator; Mitchell Cancer Institute; University of South Alabama, Mobile, Alabama

Nucleotide excision repair; and, the pharmacologic manipulation of DNA damage and repair by anticancer agents.

Highly Cited Publications:

Ovarian Cancer:
1. Dabholkar, M., Vionnet, J.A., Bostick-Bruton, F., Yu, J.J., and Reed, E. mRNA Levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemotherapy. J Clin Invest, 94:703-708, 1994. Cited more than 270 times

2. Kohn, E.C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S., Rothenberg, M., Adamo, D.O., Davis, P., Ognibene, F., Cunnion, R., and Reed, E. Taxol: High dose intensity increases the objective response rate in platinum-resistant ovarian cancer patients. J Nat’l Cancer Inst, 86:18-24, 1994. Cited more than 140 times

3. Reed E. Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy. Cancer Treatment Reviews, 24:331-344, 1998. Cited more than 180 times

Prostate Cancer:
4. Figg W D, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg S, Jones E, Premkumar A, Linehan M, Floeter M K, Chen C, Dixon S, Kohler D, Kruger E, Gubish E, Pluda J, and Reed E. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen independent prostate cancer. Clinical Cancer Research, 7:1888 – 1893, 2001. Cited more than 220 times

5. Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg W D, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small E J, Smith M R, Trump D L, Vollmet R, Wilding G. Eligibility and response guidelines for phase II clinical trials in adrogen independent prostate cancer: recommendations from the PSA working group. J Clin Oncol, 17(11):3461-3467, 1999. Cited more than 610 times

Other Selected Publications (from >300):
1. Kudo K, Gavin E, Das S, Amable L, Shevde-Samant L A, and Reed E. Inhibition of Gli1 results in altered c-jun activation, inhibition of cisplatin-induced up-regulation of ERCC1, XPD, and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene. 2012 Jan 23. doi: 10.1038/onc.2011.610. [Epub ahead of print] PMID:22266871

2. Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros W, Mueller MD, Yu JJ. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Reports 27:286-292, 2012. PMID:21971700

3. Reed E and Chabner B A. Cisplatin, Carboplatin, and Oxaliplatin. IN (Chabner BA and Longo DL, eds) Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th Edition. Lippincott, Williams & Wilkins, Philadelphia, pp 310-322, 2011.

4. Reed E. Cisplatin, and platinum analogs. IN: (V T DeVita, S A Rosenberg, T S Lawrence, eds) Cancer Principles and Practice of Oncology; 9th Edition. Lippincott, Williams, and Wilkins; Philadelphia, pp 386-392, 2011.

5. Reed E. DNA damage and repair in translational oncology: an overview. Clin Cancer Res 16:4511-4516, 2010.

6. Gao R, Price D K, Dahut W L, Steinberg S M, Reed E, and Figg W D. Genetic polymorphisms in XRCC1 associated with clinical response to radiation therapy in prostate cancer. Cancer Biology & Therapy, 10:13-18, 2010.

Top of page

---

Usablenet Assistive is a UsableNet product. Usablenet Assistive Main Page.